Viral load and immune response dynamics in patients with haemorrhagic fever with renal syndrome  by Korva, M. et al.
Viral load and immune response dynamics in patients with haemorrhagic
fever with renal syndrome
M. Korva1, A. Saksida1, N. Kejzar2, C. Schmaljohn3 and T. Avsˇicˇ–Zˇupanc1
1) Institute of Microbiology and Immunology, 2) Institute for Biostatistics and Medical Informatics, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
and 3) US Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD, USA
Abstract
Haemorrhagic fever with renal syndrome (HFRS) in Slovenia can be caused by infectionwith eitherDobrava (DOBV) or Puumala (PUUV) virus,
but a clear difference in disease severity is observed.We hypothesized that the wide spectrum of disease observed among HFRS patients might
be related to differing immune responses and viral load kinetics. To test this hypothesis we analysed sequential blood samples from 29 HFRS
patients hospitalized in Slovenia. Measuring viral RNA in patient samples revealed that viraemia lasts for longer than previously believed, with
DOBV or PUUV-infected patients having viraemias lasting on average 30 days or 16 days, respectively. DOBV-infected patients were found to
have a higher viral load than the PUUV-infected patients (107 vs. 105 RNA copies/mL). Both DOBV and PUUV-infected patients had IgM at the
time of hospital admission, but there was a difference in IgG antibody dynamics, with only a minority of DOBV-infected patients having IgG
antibodies. In our study, elevated levels of IL-10, TNF-a and IFN-cwere detected in all of the samples regardless of the causative agent. InDOBV-
infected patients the decrease in cytokine secretion level appeared around day 20 post-infection, while in PUUV-infected patients the change
was earlier. In general, our findings point toward notable differences between PUUV and DOBV infections, in terms of viral load and antibody
and cytokine response dynamics, all of which may be reflected in differing disease severities and clinical outcomes.
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Introduction
Human hantavirus infections can result in two different clinical
syndromes depending on the causative agent involved, namely
hantavirus (cardio) pulmonary syndrome (HCPS) in the
Americas and haemorrhagic fever with renal syndrome (HFRS)
in Europe and Asia [1]. In general, HFRS is clinically charac-
terized by a sudden onset of acute fever, headache, back and
abdominal pain, myalgia, nausea, vomiting and transient myo-
pia. In more severe cases, acute renal insufficiencies, requiring
treatment with transient haemodialysis, and haemorrhagic
manifestations, due to capillary leakage, are observed [2,3].
Hantaviruses have been documented to infect endothelial cells,
causing a viraemia that typically clears within the first 2 weeks
after the first appearance of symptoms [4,5]. The virus has no
direct cytopathic effect on primary cell targets; therefore host
immune mechanisms seem to play an important role in the
pathogenesis [2,6]. Monocytes and macrophages appear to
play roles both in systemic immunity to hantavirus infections
and in pathogenesis through the release of cytokines and
chemokines [7]. Several studies have shown the presence of
elevated levels of TNF-a, IL-6, IL-2, IL-1 and IL-10 in HFRS
patients [7–10]. Although humoral immune responses to
hantaviruses are generally associated with protective immu-
nity, an efficient CD8+T-lymphocyte response has also been
observed in HFRS patients early in the course of disease
[11,12]. In a longitudinal study of primary CD8+ T-cell
responses of HFRS patients from the first onset of clinical
symptoms until viral clearance, vigorous CD8+ T-cell
responses were detected during the first 2 weeks of illness.
A subsequent decline in effector CD8+ T-cells coincided with
a decline in viral load and clearance of the virus from the
infected patients. Regulatory CD4+ T-cells remained stable
throughout the course of infection [12]. Thus, it was proposed
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that a mixed pattern of Th1 and Th2 immune responses, high
levels of pro-inflammatory cytokines and the absence of
immunoregulatory mechanisms contribute to pathogenesis and
lead to the severe disease form [4,7,12]. In Slovenia, HFRS is
caused by the Puumala virus (PUUV) and Dobrava virus
(DOBV). The clinical severity of the disease caused by PUUV is
significantly lower than that of HFRS due to DOBV [10,13–15].
Likewise, higher viral load levels were demonstrated in
patients infected with DOBV than in those infected with
PUUV, but there was no correlation between the level of
antibody responses and the clinical course of the disease in these
patients [16]. Comparing cytokine profiles revealed higher levels
of IL-10 and TNF-a in DOBV-patients with severe HFRS than in
those infected with PUUV. In contrast, higher levels of IL-12
were detected in patients infected with PUUV [10].
To further define factors that contribute to severe HFRS,
we have investigated differences in the kinetics of viral load,
antibody responses and cytokine responses of DOBV and
PUUV-infected HFRS patients during the disease progression.
We hypothesized that differences in immune responses and
viral load dynamics might lead to diverse disease progression.
Here we present the results of our analysis of daily clinical
samples that were prospectively collected from patients at
their first presentation at the regional hospital with acute
symptoms and during the entire time of hospitalization until
the viral infection was resolved.
Materials and Methods
Collection of human blood and serum samples
The study was performed on 29 hospitalized HFRS patients,
18 infected with PUUV and 11 infected with DOBV. Patients
included in the study met the following inclusion criteria: (a)
verified diagnosis of acute hantavirus infection with immuno-
fluorescence assay [13]; (b) hospitalization due to manifest
HFRS; and (c) access to daily sequential samples of peripheral
blood during the hospitalization time. The study was
approved by the National Medical Ethics Committee and also
written or oral informed consent was obtained from all
included patients. In all, we have collected 183 blood samples
from 18 HFRS patients infected with PUUV and 204 blood
samples from 11 HFRS patients infected with DOBV. After
each patient was discharged from the hospital, a detailed
medical chart was collected and significant laboratory param-
eters were analysed.
Viral load dynamics
Total RNA was extracted from blood samples with TRIZOL
LS Reagent (Invitrogen Life TechnologiesTM, Foster City, CA,
USA) in accordance with the manufacturer’s instructions. The
viral load was measured in daily samples of whole blood using
Quantitative One-Step real-time reverse transcriptase poly-
merase chain reaction to detect and quantify DOBV and PUUV
genomes [17,18].
Antibody dynamics
The IgM and IgG antibodies against DOBV and PUUV were
detected using commercially available enzyme immunoassays:
Reagena DOBRAVA-HANTAN IgM EIA, Reagena DOBRAVA-
HANTAN IgG EIA, Reagena PUUMALA IgM EIA and Reagena
PUUMALA IgG EIA (Reagena International Oy Ltd, Toivala,
Finland). The test was performed according to the manufac-
turer’s instructions. A cut-off value for IgM is R > 1 and for IgG
is R > 1.2. Based on our experiences, the average value
measured, at admission to the hospital, is 2.8 (max 8.8) for IgM
and 2.3 (max 5.0) for IgG.
Cytokine detection
Levels of IL-10, IL-12, IFN-c and TNF-a were measured in
plasma samples with commercial ELISA tests. Namely, for the
determination of IL-10, IL-12 and INF-c, the Human IL-10 ELISA
kit, Total Human IL-12 ELISA kit and Human IFN-c ELISA kit (all
Thermo Fisher Scientific Inc., Waltham, MA, USA) were used.
The TNF-a ELISA kit (BioSource Europe S.A., Nivelles, Belgium)
was used to measure TNF-a concentrations. The limits of
detection, as declared by the manufacturer, for IL-10, IL-12,
IFN-c and TNF-a were <3 pg/mL, <5 pg/mL, <2 pg/mL and
<3 pg/mL, respectively. Normal values, measured in plasma
samples of Slovenian healthy adult blood donors, for IL-10, IL-
12, IFN-c and TNF-a were determined to be <10.8 pg/mL,
<203 pg/mL, <1.1 pg/mL and 4.76–12.4 pg/mL, respectively.
Statistical methods
All statistical analyses were performed using the R environ-
ment [19]. A statistical confidence level a of 0.05 was
considered. Smooth lines in graphs were calculated by the
loess smoothing procedure (local polynomial regression fitting
[20]) in order to get an impression of general time trends in
the data. Exploratory mixed-effects regression models (R
package nlme) were used to identify statistically significant
associations between viral load in time and a response variable
(one of IgM, IgG antibody kinetic or cytokine response
kinetics). In these models each patient is represented by a
random effect with correlation modelled by the AR(1) process.
Predictor variables (time and viral load) are considered to be
either linear or non-linear (via restricted cubic splines
formulation (R package rms)) [21]. As most patients were
dismissed from the hospital before day 41 the measurements
after that were omitted from the statistical analyses.
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Results
Patients and clinical data
Twenty-nine HFRS patients hospitalized in Slovenia during the
years 2007 and 2010 participated in the study. During the same
period 83 cases of HFRS were confirmed in Slovenia. Based on
clinical data and laboratory parameters [15,17] the disease
progression was evaluated. Among 18 patients infected with
PUUV, 10 patients were categorized as mild-to-moderate and
eight patients as severe disease manifestations. In the DOBV-
infected HFRS patients, one patient had a fatal outcome, three
patients experienced the severe form of the disease and seven
patients had mild-to-moderate disease. This study group
exemplified the representative number of patients with
different clinical manifestations existing in Slovenia according
to historical data.
In the PUUV-infected patients, the mean time from onset of
symptoms until hospital admission was 4.7 days, and the mean
time of hospitalization was 10.4 days. The longest hospitaliza-
tion time was 30 days for the patient experiencing the severe
form of HFRS with many complications, including: transient
blindness, severe lumbar pain and meningitis. In the DOBV-
infected patients, the mean time from the onset of the disease
until hospitalization was 6.6 days and the mean hospitalization
time was 28.5 days. The longest hospitalization time was
75 days, for the patient experiencing severe disease manifes-
tations that led to chronic renal impairment. The most
common symptoms and significant laboratory parameters for
both groups of patients are shown in Table 1.
Kinetic of viral load
In all patients the viral load decreased with disease progres-
sion. In DOBV-infected patients the longest duration of
viraemia observed was 40 days post-infection. All DOBV-
infected patients were viraemic on the first 12 days post-
infection, and most patients had detectable viral RNA in their
blood up to 30 days post-infection (Fig. 1, above left). Most of
the patients were dismissed from hospital care before the virus
was cleared from the blood system. In addition, at admission all
DOBV-infected patients had more than 107 RNA copies/mL
(Table 1). The highest viraemia, 2.5 9 1010 RNA c/mL, was
measured on the fifth day of illness in the DOBV-infected fatal
patient (Fig. 1, below left, green line). As expected, in PUUV-
infected patients the mean interval of viraemia was shorter,
16 days post-infection. PUUV-infected patients were generally
hospitalized for shorter times than DOBV-patients; however,
for one PUUV-patient, viraemia was detected at 30 days post-
infection. The mean viral load in PUUV-infected patients was
105 RNA c/mL (Table 1). The highest viral load was
1.03 9 1010 RNA c/mL, measured on the seventh day of
illness in a patient with severe disease progression (Fig. 1,
below right, green line).
In both groups the initial decrease in viral load was observed
in the first few days after admission to the hospital, but in
PUUV-infected patients the virus clearance was more rapid.
Also, clear differences between patients in each group were
observed, especially among the PUUV-infected patients (Fig. 1,
below). We also observed interesting viral load kinetics in
three patients infected with DOBV and five patients infected
with PUUV, where an initial decrease in viraemia was followed
by another increase (Fig. 1, below steep drops followed by
steep increases). We were unable to correlate this observa-
tion with any specific treatment or therapy, or with clinical
severity or antibody dynamics (data not shown). Three out of
eight patients had underlying disease, such as rheumatoid
arthritis, diabetes or arteriosclerotic vascular disease with
chronic hypertension, which could influence the immune
response.
IgM and IgG antibody kinetics
Puumala-infected patients were admitted to hospital care
between 3 and 11 days after the onset of disease. On
admission all patients had anti-PUUV IgM and 13 patients had
IgG antibodies. DOBV-infected patients presented for hospital
TABLE 1. Comparison of different clinical, laboratory and
microbiological findings in Dobrava virus (DOBV) and Puu-
mala virus (PUUV)-infected groups of patients
Virus PUU DOB
Time before hospital
admission (days)
4.7 6.6
Duration of
hospitalization (days)
10.4 28.5
Most common
symptoms at admission
High fever, vomiting,
severe lumbalgia and
abdominal pain,
blurred vision,
impaired renal
function
High fever, chills,
severe lumbalgia
and abdominal
pain, severe
impairment of
renal function,
conjunctival
injections
Number of patients
requiring haemodialysis
1 (5.6%) 5 (45.5%)
Laboratory findings
Min platelets (mean value) 68 9 109/L 44 9 109/L
Max creatinine (mean value) 349.5 µM 593.1 µM
Max urea (mean value) 17.3 µM 28.5 µM
Max AST/ALT (mean value) 1.1/1.6 µkat/L 1.8/1.7 µkat/L
Microbiological findings
Duration of viraemia (days) 16 30
Viral load (mean value) 105 RNA copies/mL 107RNA copies/mL
IgM (mean value) 3.90 2.97
IgG (mean value) 2.12 1.44
IL-10 (mean value)
min/max value
400.4 pg/mL
1.1/5444.80 pg/mL
132.3 pg/mL
0.62/6000.0 pg/mL
IL-12 (mean value)
min/max value
70.9 pg/mL
0.0/242.1 pg/mL
84.0 pg/mL
0.0/291.1 pg/mL
TNF-a (mean value)
min/max value
44.4 pg/mL
1.0/451.5 pg/mL
64.9 pg/mL
14.2/237.2 pg/mL
INF-c (mean value)
min/max value
4.2 pg/mL
0.0/38.0 pg/mL
6.4 pg/mL
0.0/90.4 pg/mL
ª2013 The Authors
Clinical Microbiology and Infection ª2013 European Society of Clinical Microbiology and Infectious Diseases, CMI, 19, E358–E366
E360 Clinical Microbiology and Infection, Volume 19 Number 8, August 2013 CMI
care between 4 and 11 days after the onset of disease. On
admission all patients had anti-DOBV IgM antibodies, but only
three had detectable IgG antibodies. The IgM and IgG mean
values are shown in Table 1. DOBV-infected patients had
lower humoral responses than PUUV-infected patients, but the
kinetics of antibody development was more apparent (Fig. 2).
FIG. 1. Mean kinetic of viral load in
patients infected with Dobrava virus
DOBV (left) and Puumala virus PUUV
(right). In the lower two figures the
kinetics of viral load in a single patient
infected with DOBV (left) and PUUV
(right) is presented.
FIG. 2. IgM and IgG antibody response
against Dobrava virus (DOBV) and
Puumala virus(PUUV) infection in plasma
samples of haemorrhagic fever with renal
syndrome(HFRS) patients.
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The DOBV patients displayed clear time dependence for the
appearance of IgM and IgG antibodies, where the IgM response
was decreasing and the IgG response was increasing as the
infection progressed. Although the kinetics of the IgG antibody
response between PUUV and DOBV-infected patients was
different, in the DOBV-infected patients the IgG response was
constantly increasing in relation to the day of illness, but in the
PUUV-infected patients a plateau appeared to be reached after
25 days post-infection. A non-linear negative association using
the mixed-effects regression model (p <0.01) was observed
between IgG responses and viral loads in DOBV-infected
patients, in which a high viral load was associated with low IgG,
regardless of the day of disease. The shape of the mean IgG
response for the regression model where the day of illness and
viral load were treated as non-linear can be seen in Fig. 3. No
statistically significant association with viral load was observed
for IgM responses in DOBV-infected patients or in IgM or IgG
response in PUUV-infected patients.
Cytokine response kinetics
Elevated levels of IL-10, TNF-a and IFN-c were detected in
almost all of the samples tested, regardless of the causative
hantavirus (Table 1, Fig. 4). In DOBV-infected patients
elevated cytokines slowly declined to a level of healthy blood
donors at around 20 days post-infection. However, in PUUV-
infected patients a change in cytokine dynamic was observed
earlier, around day 10 post-infection. In DOBV-infected
patients concentrations of IL-10, except for the fatal case,
were lower than in PUUV-infected patients (22.4 vs. 400.4 pg/
mL). Also in DOBV-infected patients a negative time depen-
dence of IL-10 was observed, in contrast to PUUV-infected
patients, where elevated levels of IL-10 seem to persist during
the hospitalization time (Fig. 4, row 1). A significant association
was observed between highly non-linear viral load dynamics
and secretion of IL-10, where increase in viral load led to
higher production of IL-10 regardless of the causative agent (p
0.04) (Fig. 5). Overall, all DOBV and PUUV-infected patients
had levels of TNF-a high above the values of healthy blood
donors during the whole hospitalization time, despite there
being a trend toward negative time dependence for first
25 days (Fig. 4, row 2). An exception was the DOBV-infected
fatal patient, where TNF-a concentrations increased as the
disease progressed. The mean concentrations of TNF-a were
higher in DOBV than PUUV-infected patients (64.9 vs. 44.4 pg/
mL). The highest dynamic was observed for IFN-c concentra-
tions, which in most patients increased and decreased
vigorously almost daily. On average, higher concentrations of
IFN-c were detected in patients infected with DOBV than
PUUV (6.4 vs. 4.2 pg/mL). Namely, in PUUV-infected patients,
concentrations of IFN-c showed negative time dependence,
but in some DOBV-infected patients a second increase after
day 20 was observed (Fig. 4, row 3). The increase in IFN-c
concentrations follows the increase in viral load, but the
models show no statistically significant association. Further-
more, in four patients (3 DOBV and 1 PUUV) IFN-c could not
be detected at all during the whole hospitalization.
In contrast to other cytokines, concentrations of IL-12 were
decreased in comparison to levels measured in healthy blood
donors (84.0 and 70.9 vs. 203 pg/mL) (Fig. 4, row 4).
Considering the dynamic of IL-12 secretion, we have observed
association between viral load and IL-12, where higher viral
load is associated with higher IL-12 secretion (p 0.01).
Discussion
The mechanism behind hantavirus pathogenesis is not com-
pletely understood. Hantaviruses primarily infect endothelial
cells lining the vascular system and cause increased perme-
ability followed by capillary leakage. As hantaviruses are not
cytopathogenic per se it has been suggested that host immune
mechanisms directed against the infection cause the vascular
permeability [2,6]. For both HFRS and HCPS patients, a
correlation between higher viral load levels and the severity of
the disease has been reported [17,22]. For HFRS, a wide
spectrum of clinical disease is observed, thus it is possible that
differences in immune response dynamics between HFRS
patients infected with DOBV or PUUV might lead to diverse
disease progressions and that viral load is also a contributing
factor to those differences. To investigate this hypothesis, we
FIG. 3. Shape of mean IgG response for the regression model where
the day of illness and viral load were treated as non-linear. The scale
on the y-axis corresponds to the fifteenth day of illness.
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collected sequential blood samples from 29 HFRS patients
hospitalized in Slovenia (18 PUUV and 11 DOBV). Our study
results are consistent with previous findings [13,14] that
DOBV is responsible for the severe form of HFRS in Slovenia,
because the patients have advanced renal impairment and
therefore more frequently require haemodialysis (Table 1).
FIG. 4. Mean dynamic of IL-10, TNF-a, IFN-c and IL-12 in plasma samples of haemorrhagic fever with renal syndrome(HFRS) patients during the
entire hospitalization time. The red line represents cytokine concentrations measured in healthy blood donors in Slovenia.
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Also, all clinical parameters relating to kidney and liver function
are higher in DOBV-infected patients than in PUUV-infected
patients and the DOBV patients are hospitalized for longer
periods of time.
Although DOBV and PUUV-infected patients both had IgM
at the time of hospital admission, there was a difference in the
subsequent viral loads, with DOBV-infected patients having
much higher levels than PUUV patients. Therefore, our results
are consistent with earlier studies indicating that more virulent
hantaviruses (like DOBV and SNV) tend to have higher viral
loads [17,22]. Contrary to the generally accepted fact that
viraemia in HFRS and HCPS patients lasts only a few days
[5,12,23], our study showed that viraemias in DOBV or
PUUV-infected patients averaged 30 days (max. 40 days) and
16 days (max. 30 days) post-infection, respectively. In addition
to the unexpectedly prolonged viraemias in both groups of
patients, differing viral kinetics were also observed. In DOBV-
infected patients, after an initial drop in viral load, which
occurred after a few days of hospitalization, the viral load
tended to stabilize. In contrast, in the PUUV-infected patients
the viral load continued to drop throughout the hospitalization
period. Interestingly, all patients entered the convalescent
phase before they were discharged from the hospital, but most
of them still had detectable viral loads, especially those infected
with DOBV.
Highly variable viral loads were observed among patients in
both groups, which suggest that a host–virus interaction could
be a factor in the pathogenesis seen in individual patients. The
correlation between host immune genetics, especially HLA
type and TNF-a polymorphism, and the severity of or
susceptibility to hantavirus infection has already been shown
for several hantaviruses, including DOBV and PUUV [15,24–
27]. In addition, in some HFRS patients, the virus seemed to be
temporarily cleared, but this was usually followed by a second
period of viraemia. This is similar to what we commonly
observe in experimentally infected hamsters (data not shown),
and we surmise that the second viraemia is the result of viral
replication in target tissues and release of additional infectious
virions. In the study reported here, we could not correlate this
observation with medical treatment, severity of the disease or
any underlying disease.
Consistent with earlier studies, we found that the humoral
immune response to infection is already present when the first
symptoms of HFRS appear [18,28,29], consequently the
antibodies do not appear to completely control viral load
kinetics. There was a difference in antibody kinetics, however,
in that while most PUUV-infected patients had IgG antibodies
at admission, only a minority of DOBV-infected patients had
IgG antibodies. In addition, DOBV patients had lower IgG
antibody responses in general than PUUV patients and
displayed a rapid decrease in IgM. Although observed differ-
ences between DOBV and PUUV-infected patients could be
also influenced by the quality of commercial ELISAs, we believe
that at least this is not the only factor in such observations,
mainly because a low IgG response was correlated with a high
viral load for the DOBV-infected patients but not for the
PUUV-infected patients.
It is generally accepted that neutralizing antibodies are a
primary correlate of protective immunity for HFRS. However,
once HFRS is established, the humoral immune response may
not be sufficient to resolve the disease. The importance of a
robust cell-mediated response is supported by earlier studies
in which it was shown that a decline in effector CD8+ T-cells
coincided with decline in viral load and clearance of the virus
from HFRS patients [12]. Besides clearing the viral infection,
CD8+ T-cells are also a rich source of cytokines and
chemokines, such as TNF-a and IFN-c [30]. In HFRS patients
several studies have shown elevated levels of TNF-a, IL-6, IL-2,
IL-1 and IL-10 patients [7–10]. In our study, elevated levels of
IL-10, TNF-a and IFN-c were detected in all of the samples
regardless of the causative agent. Again, differences in both
groups of patients were observed; in DOBV-infected patients
the decrease in cytokine secretion level appeared around day
20 post-infection, while in PUUV-infected patients the change
was earlier. In agreement with the work of others [9,29,30] we
observed increased levels of TNF-a in both DOBV and PUUV-
infected patients. Although the increased levels of TNF-a were
observed in both groups, there was no association with viral
load in our study. We did observe a significant correlation
FIG. 5. The shape of the mean response of IL-10 for the regression
model where the day of illness was treated as a linear and log viral load
as a non-linear effect. The scale on the y-axis corresponds to the tenth
day of illness.
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between the viral load dynamics and secretion of IL-10; an
increase in viral load led to higher production of IL-10. IL-10
displays a potent ability to suppress the antigen-presentation
capacity of antigen presenting cells. Although IL-10 is an anti-
inflammatory cytokine and is capable of inhibiting synthesis of
pro-inflammatory cytokines such as IFN-c and TNFa, there
was no association of IL-10 and IFN-c or TNF-a observed in
studied patients.
Another potent mediator of immunopathogenesis, NK cells,
is activated by IFN-a, IFN-b, TNF-a, IL-12 and IL-15. In
addition, NK cells can also influence the adaptive immune
response directly by secreting IFN-c [31]. IFN-c has been
shown to inhibit HTNV replication in vitro, and in PUUV-
infected patients IFN-c was found to be significantly decreased
in the acute phase of HFRS [32]. In our study, IFN-c dynamics
changed almost daily in observed patients. On average, in most
DOBV and PUUV-infected patients elevated concentrations of
IFN-c, in comparison to healthy blood donors, were measured,
although in four patients with severe disease progression, IFN-
c could not be detected for almost the entire length of the
patients’ hospitalization. Our data suggest that concentrations
of IFN-c from different patients, measured in the early or late
phase of acute HFRS, cannot be correlated with each other, as
there are obvious differences between patients.
Consistent with earlier data [7], we observed a decrease in
most measured cytokines in PUUV-infected patients during
the late phase of acute disease. Interestingly, in DOBV-
infected patients increases in measured cytokines during the
late phase of disease were observed. In general, our findings
point toward notable differences between PUUV and DOBV
infections, in terms of viral load and antibody and cytokine
response kinetics, all of which may be reflected in differing
disease severities and clinical outcomes. The disparity between
pro- and anti-inflammatory cytokines might be in part
responsible for the pathology seen in HFRS patients, but the
extreme variations observed among patients suggest that
other factors, such as host genetics, are also important. This is
also the reason why we believe that serial samples from single
patients are the only way to obtain meaningful data comparing
different biological factors in the early and late phases of the
disease.
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